{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:14:18Z","timestamp":1788880458338,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","award":["24114"],"award-info":[{"award-number":["24114"]}],"id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103047","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:03:46Z","timestamp":1785773026000},"page":"103047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Givinostat enhances antisense oligonucleotide efficacy in the mdx52 model of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"37","author":[{"given":"Xaysongkhame","family":"Phongsavanh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Mottais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Doisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Le Coz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Spitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-1165","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Goyenvalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103047_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cupe.2005.04.001","article-title":"The multidisciplinary management of Duchenne muscular dystrophy","volume":"15","author":"Bushby","year":"2005","journal-title":"Curr. Paediatr."},{"key":"10.1016\/j.omtn.2026.103047_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103047_bib3","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2026.103047_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2026.103047_bib5","first-page":"835","article-title":"Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications","volume":"45","author":"Den Dunnen","year":"1989","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2026.103047_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1006\/geno.1997.4911","article-title":"Exon-intron organization of the human dystrophin gene","volume":"45","author":"Nobile","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.omtn.2026.103047_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/338259a0","article-title":"Association of dystrophin and an integral membrane glycoprotein","volume":"338","author":"Campbell","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103047_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s42003-022-03980-y","article-title":"The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction","volume":"5","author":"Wilson","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtn.2026.103047_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1083\/jcb.122.4.809","article-title":"A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin","volume":"122","author":"Ervasti","year":"1993","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103047_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fgene.2011.00064","article-title":"Dystrophin Orchestrates the Epigenetic Profile of Muscle Cells Via miRNAs","volume":"2","author":"Marrone","year":"2011","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtn.2026.103047_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1180980","article-title":"Satellite cell contribution to disease pathology in Duchenne muscular dystrophy","volume":"14","author":"Kodippili","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2026.103047_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","article-title":"HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients","volume":"30","author":"Mozzetta","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2026.103047_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng0493-283","article-title":"The structural and functional diversity of dystrophin","volume":"3","author":"Ahn","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2026.103047_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nrm2024","article-title":"Molecular mechanisms of muscular dystrophies: old and new players","volume":"7","author":"Davies","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103047_bib15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2353\/ajpath.2009.080460","article-title":"PTEN Contributes to Profound PI3K\/Akt Signaling Pathway Deregulation in Dystrophin-Deficient Dog Muscle","volume":"174","author":"Feron","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2026.103047_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev.physiol.010908.163216","article-title":"Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies","volume":"71","author":"Wallace","year":"2009","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.omtn.2026.103047_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jcm10040820","article-title":"Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy","volume":"10","author":"Fortunato","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2026.103047_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2026.103047_bib19","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2026.103047_bib20","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1039\/D4MD00394B","article-title":"The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy","volume":"15","author":"Blitek","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.omtn.2026.103047_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103047_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1126\/science.aba4515","article-title":"RNA-targeted drugs for neuromuscular diseases","volume":"371","author":"Ferlini","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103047_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/nar\/gkab1199","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"50","author":"Relizani","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103047_bib24","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.3347839","article-title":"Expression of the murine Duchenne muscular dystrophy gene in muscle and brain","volume":"239","author":"Chamberlain","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103047_bib25","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1073\/pnas.192571199","article-title":"Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle","volume":"99","author":"Haslett","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103047_bib26","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1096\/fj.13-232025","article-title":"DMD transcript imbalance determines dystrophin levels","volume":"27","author":"Spitali","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2026.103047_bib27","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103047_bib28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/nar\/24.15.3059","article-title":"Stability of the human dystrophin transcript in muscle","volume":"24","author":"Tennyson","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103047_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.molcel.2005.08.012","article-title":"Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements","volume":"20","author":"Gehring","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2026.103047_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: First Approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.103047_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol. Med."},{"key":"10.1016\/j.omtn.2026.103047_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2026.103047_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.omtn.2022.11.017","article-title":"Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice","volume":"30","author":"Bizot","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103047_bib34","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.3390\/ijms26062583","article-title":"Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice","volume":"26","author":"Phongsavanh","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103047_bib35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1006\/bbrc.1997.7328","article-title":"Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy","volume":"238","author":"Araki","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2026.103047_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105751","article-title":"Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy","volume":"170","author":"Giovarelli","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.omtn.2026.103047_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-08539-x","article-title":"Transcriptional adaptation upregulates utrophin in Duchenne muscular dystrophy","volume":"639","author":"Falcucci","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103047_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.106306","article-title":"The complexity of dystrophin transcription and processing: implications of transcript imbalance on dystrophin gene targeting strategies","volume":"59","author":"Rossi","year":"2026","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.103047_bib39","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.omtm.2020.04.025","article-title":"Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice","volume":"17","author":"Aupy","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.103047_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omtn.2023.03.009","article-title":"Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mdx52 mice","volume":"32","author":"Saoudi","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103047_bib41","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.3390\/biomedicines11123243","article-title":"Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model","volume":"11","author":"Doisy","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2026.103047_bib42","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2026.103047_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study","volume":"10","author":"Clemens","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2026.103047_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/22143602251366721","article-title":"Association between exon-skipping therapy with eteplirsen and cardiac outcomes in Duchenne muscular dystrophy","volume":"13","author":"Iff","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2026.103047_bib45","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1503\/cmaj\/051291","article-title":"Troponin: the biomarker of choice for the detection of cardiac injury","volume":"173","author":"Babuin","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.omtn.2026.103047_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mus.28444","article-title":"A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy","volume":"72","author":"Donovan","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2026.103047_bib47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.103047_bib48","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103047_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2044-5040-1-34","article-title":"Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders","volume":"1","author":"Mamchaoui","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2026.103047_bib50","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1093\/hmg\/ddv214","article-title":"Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies","volume":"24","author":"Rouillon","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103047_bib51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:04:37Z","timestamp":1788879877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126002180"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103047","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Givinostat enhances antisense oligonucleotide efficacy in the mdx52 model of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103047"}}